Tucotuzumab (75 μg; intratumoral injection; 5 daily of 15 μg (total dose of 75 μg), each in 50 μL PBS; on days 10 and 14) results in significantly greater tumor growth suppression and enhances survival[1].
| Animal Model: | Female Balb/c mice bearing CT26-KS colon adenocarcinoma[1] |
| Dosage: | 75 μg |
| Administration: | Intratumoral injection; 5 daily of 15 μg (total dose of 75 μg), each in 50 μL PBS; on days 10 and 14 |
| Result: | Resulted in significantly greater tumor growth suppression and enhanced survival.
|
